Cencora says additional data stolen in February cyberattack
U.S. drug distributor Cencora said on Wednesday additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and data breach that happened in February.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Chairman, President & Chief Executive Officer Bob Mauch - Executive Vice President & Chief Operating Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Eric Percher - Nephron Research Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Daniel Grosslight - Citi George Hill - Deutsche Bank Stephanie Davis - Barclays Eric Coldwell - Baird Kevin Caliendo - UBS Operator Good morning and good afternoon, ladies and gentlemen. Welcome to the Cencora Q3 Earnings Call.
Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $2.92 per share a year ago.
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cencora (COR) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Cencora (COR) is Poised to Beat Earnings Estimates Again
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
